s / The Breast 23 (2014) S1eS6 S5 FACTORS PREDICTING THE NODAL INVOLVEMENT IN EARLY BREAST CANCER A. Elmadahm, P. Gill , G. Farshid , V. Gebski , M. Bilous , S. Lord , L. Chee , N. Wetzig . University of Adelaide, North Terrace, Adelaide, SA, Australia; NHRMC Clinical trial Centre, University of Sydney, Sydney, NSW, Australia; 3 Sydney Medical School, University of Sydney, Sydney, NSW, Australia; Wesley Medical Centre, Brisbane, QLd, Australia Background: The nodal status is an important prognostic factor in early breast cancer. This study assessed association between clinicopathological factors and involvement of Sentinel Lymph Node (SLN) and Non Sentinel Lymph Node (NSLN) in the SNAC 1 trial. Accurate statistical models can assist surgical counselling and potentially avoid axillary surgery in selected cases. Method: This is a retrospective analysis of 1088 patients. Lymphoscintigraphy, blue dye injection and gamma probe were used for SLN mapping and retrieved nodes were examined with HE 16:266-75. TREATMENT DELAY FOR M AORI WOMEN WITH BREAST CANCER IN NEW ZEALAND S.A. Seneviratne, I.D. Campbell, N. Scott, R. Lawrenson. Waikato Clinical School, University of Auckland, New Zealand Background: Delays in diagnosis and treatment of breast cancer are associated with lower survival rates 1. Indigenous M aori women have 60% higher overall and 32% higher stage adjusted breast cancer mortality compared to European women in New Zealand (NZ) 2. We sought to evaluate factors associated with delays of >31 and >90 days for surgical treatment of breast cancer among NZ womenwith newly diagnosed breast cancer. Methods: A retrospective analysis of prospectively collected data included in the Waikato Breast Cancer Register from 01/01/2005 through 31/12/ 2010 was performed. Results: 1449 (out of 1510, 96%) breast cancers diagnosed within Waikato, over the study period were included. Out of women undergoing primary surgery (n1⁄41264), 59.6% and 98.2% underwent surgery within 31 and 90 days of diagnosis respectively. Compared with NZ European women (mean 30.4 days), significantly longer delays for surgical treatment were observed among M aori (mean 36.9, p with NZ European women, higher proportions of M aori and Pacific Island women (statistically non-significant) experienced delays longer than 31 days (40.2% vs. 47.8% and 52.1%, P>0.05) and 90 days (1.6% vs. 2.7% and 4.3%, p>0.05). Multivariate analysis identified public sector treatment (OR 5.93 and 8.14), DCIS (OR 1.53 and 3.17), mastectomy as treatment (OR 1.75 and 6.60) and earlier year of diagnosis (1.21 and 1.03) as factors significantly associated with delays longer than 31 and 90 days. Conclusions: A high proportion of women not initiating surgical treat- ment of breast cancer within the stipulated guideline limit of 31 days and significantly longer delays experienced by ethnic minority women were highlighted in this study. Urgent steps are needed to improve performance and to shorten treatment delays in public sector to minimize delays overall, and to reduce ethnic inequities in breast cancer treatment in NZ.